Your search history is turned on.
Date: May 7, 2021 Jurisdictions: Alberta, British Columbia, Manitoba, Nova Scotia, Ontario
Trillium Therapeutics Reports First Quarter 2021 Operating and Financial Results CAMBRIDGE, Mass., May 07, 2021 (GLOBE NEWSWIRE) -- Trillium Therapeutics Inc. (NASDAQ/TSX: TRIL), a clinical stage immuno-oncology company developing innovative therapies for the treatment of cancer, today reported financial and operating results for the three months ended March 31, 2021. All financial amounts in this news...
Microsoft Word - Q1 2021 Financial Statements FINAL INTERIM CONDENSED CONSOLIDATED FINANCIAL STATEMENTS FOR THE THREE MONTHS ENDED MARCH 31, 2021 AND 2020 (UNAUDITED) 2488 Dunwin Drive Mississauga, Ontario L5L 1J9 www.trilliumtherapeutics.com TRILLIUM THERAPEUTICS INC. Condensed Consolidated Balance ...
Microsoft Word - CFO Certification Q1 2021 10-Q Exhibit 31.2 CERTIFICATION OF PRINCIPAL EXECUTIVE OFFICER PURSUANT TO RULE 13a-14(a) / RULE 15d-14(a) OF THE SECURITIES EXCHANGE ACT OF 1934, AS AMENDED I, James Parsons, certify that: 1. I have reviewed this Quarterly Report on Form 10-Q for the period ended March 31, 2021 of Trillium Therapeutics Inc.; 2. B...
Microsoft Word - CEO Certification Q1 2021 10-Q Exhibit 31.1 CERTIFICATION OF PRINCIPAL EXECUTIVE OFFICER PURSUANT TO RULE 13a-14(a) / RULE 15d-14(a) OF THE SECURITIES EXCHANGE ACT OF 1934, AS AMENDED I, Jan Skvarka, certify that: 1. I have reviewed this Quarterly Report on Form 10-Q for the period ended March 31, 2021 of Trillium Therapeutics Inc.; 2. Base...
Microsoft Word - Q1 2021 Management Discussion and Analysis FINAL MANAGEMENTS DISCUSSION AND ANALYSIS FOR THE THREE MONTHS ENDED MARCH 31, 2021 AND 2020 Dated: May 7, 2021 2488 Dunwin Drive Mississauga, Ontario, L5L 1J9 www.trilliumtherapeutics.com 1 Item 2. Managements Discussion and Analysis of Financial C...
Date: April 30, 2021 Jurisdictions: Alberta, British Columbia, Manitoba, Nova Scotia, Ontario
8th Floor, 100 University Avenue Toronto, Ontario M5J 2Y1 www.computershare.com Form of Proxy - Annual General and Special Meeting to be held on June 8, 2021 01QFNA This Form of Proxy is solicited by and on behalf of Management. Fold Fold CONTROL NUMBER To vote by telephone or the Internet, you will need to provide your CONTROL NUMBER listed below. If you vo...
Microsoft Word - Document1 TRILLIUM THERAPEUTICS INC. Notice of Annual General and Special Meeting of Shareholders NOTICE IS HEREBY GIVEN that the Annual General and Special Meeting of Shareholders (the Meeting) of Trillium Therapeutics Inc. (the Corporation) will be held on June 8, 2021, at 1:00 pm (Toronto time). The Meeting will be conducted as a virtual...
Microsoft Word - Trillium_2021 Management Information Circular(401575466.9) v9 final clean.docx UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A (Rule 14a-101) INFORMATION REQUIRED IN PROXY STATEMENT SCHEDULE 14A INFORMATION Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 ...
Date: April 28, 2021 Jurisdictions: Alberta, British Columbia, Manitoba, New Brunswick, Ontario
file:///T:/tm2114370-1/tm2114370-1_8kseq1/proof.htm Exhibit 99.2 Page 10 of 123Submission Proof - 21-14370-1 4/27/2021file:///T:/tm2114370-1/tm2114370-1_8kseq1/proof.htm Page 11 of 123Submission Proof - 21-14370-1 4/27/2021file:///T:/tm2114370-1/tm2114370-1_8kseq1/proof.htm Page 12 of 123Submission Proof - 21-14370-1 4/27/2021file:///T:/tm2...
Date: April 28, 2021 Jurisdictions: Alberta, British Columbia, Manitoba, Nova Scotia, Ontario
Trillium Therapeutics Announces Dosing of First Patient in Phase 1b Study of TTI-622 in Combination With Carfilzomib and Dexamethasone in Relapsed/Refractory Multiple Myeloma CAMBRIDGE, Mass., April 28, 2021 (GLOBE NEWSWIRE) -- Trillium Therapeutics Inc. (NASDAQ/TSX: TRIL), a clinical stage immuno-oncology company developing innovative therapies for the treatment of cancer, today announced that it has ...